Earlier this month in Madison, Wisconsin, Psychedelic Alpha’s Josh Hardman sat down with Compass Pathways’ Chief Patient Officer, Steve Levine, at a pivotal time for the company. Just a week prior, the psilocybin drug developer told investors it is bringing forward its commercialisation timeline by up to one year, following a “positive” September meeting with FDA and faster-than-anticipated…
